• LAST PRICE
    0.4066
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.4000/ 4
  • Ask / Lots
    0.4180/ 8
  • Open / Previous Close
    0.4150 / 0.4066
  • Day Range
    Low 0.4061
    High 0.4312
  • 52 Week Range
    Low 0.1947
    High 4.9100
  • Volume
    47,606
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.4213
TimeVolumeNEXI
09:32 ET12780.415
09:51 ET15000.410312
09:55 ET4570.4312
10:06 ET1190.4121
10:11 ET1000.412
10:51 ET3800.41
10:56 ET4000.4062
11:14 ET5000.4198
11:30 ET49380.4063
11:38 ET30000.4198
11:54 ET10000.4064
12:51 ET2000.4198
01:42 ET4640.4198
01:49 ET10000.4131
02:00 ET4000.4092
02:02 ET9000.4064
02:03 ET104950.4081
02:05 ET2000.4064
02:16 ET2000.4064
02:20 ET1010.4064
02:23 ET1300.4065
02:32 ET4010.407
02:39 ET57480.4064
02:43 ET10430.4064
02:52 ET51670.4082
03:01 ET1000.42
03:26 ET1000.4065
03:32 ET11450.42
03:37 ET2000.4065
03:44 ET1000.4071
03:50 ET1000.4065
03:53 ET1000.4065
03:55 ET2000.4065
03:57 ET1000.4065
04:00 ET3000.4066
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNEXI
Neximmune Inc
10.6M
-0.2x
---
United StatesIPIX
Innovation Pharmaceuticals Inc
10.8M
-1.7x
---
United StatesCING
Cingulate Inc
10.9M
-0.6x
---
United StatesTXTM
Protext Mobility Inc
10.9M
0.0x
---
United StatesBRTX
BioRestorative Therapies Inc
10.8M
-0.2x
---
United StatesKTRA
Kintara Therapeutics Inc
10.2M
-0.3x
---
As of 2023-02-01

Company Information

NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. Its T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. It is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and in disease areas outside of oncology.

Contact Information

Headquarters
9119 Gaither RoadGAITHERSBURG, MD, United States 20878
Phone
301-825-9810
Fax
302-655-5049

Executives

Independent Chairman of the Board
Sol Barer
President, Chief Executive Officer, Director
Kristi Jones
Chief Financial Officer
John Trainer
Executive Vice President - Research and Development
Jerome Zeldis
Chief Scientific Officer
Mathias Oelke

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.6M
Revenue (TTM)
$0.00
Shares Outstanding
26.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.64
Book Value
$3.67
P/E Ratio
-0.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.